Cellzome Announces Achievement of First Milestone in Epigenetics Collaboration with GSK

Cellzome announced today that it has successfully achieved the first milestone in its epigenetics alliance with GlaxoSmithKline.

Heidelberg, Germany and Cambridge, UK- 8th December 2010 – Cellzome announced today that it has successfully achieved the first milestone in its epigenetics alliance with GlaxoSmithKline. The achievement of the milestone triggers a payment from GlaxoSmithKline of an undisclosed amount.

The strategic collaboration was announced in March this year and gives GSK exclusive access to Cellzome’s proprietary Episphere? technology in the emerging field of epigenetics as applied to immuno-inflammatory disease. Under the terms of the agreement, the companies work together using Cellzome’s Episphere? technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.

Ti